Viewing Study NCT04121273



Ignite Creation Date: 2024-05-06 @ 1:48 PM
Last Modification Date: 2024-10-26 @ 1:19 PM
Study NCT ID: NCT04121273
Status: UNKNOWN
Last Update Posted: 2021-03-03
First Post: 2019-10-08

Brief Title: GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Organization: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study Overview

Official Title: Clinical Study of GPC3-targeted Chimeric Antigen Receptor T Cells fo Treating Advanced Hepatocellular Carcinoma
Status: UNKNOWN
Status Verified Date: 2021-03
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Patients with hepatocellular carcinoma a type of primary liver cancers are enrolls in this study The cancer has progressed after standard treatment or the patient cannot receive regular treatment

Investigator made a gene called chimeric antigen receptor derived from an antibody that recognizes Glypican 3 a protein detected in in a large proportion of hepatocellular carcinoma The gene will introduce into T cell from patients blood to make them recognize and kill cancer cells

The aim of this study is to evaluate the efficacy tolerance and safety of chimeric antigen receptor-modified T CAR-T cell targeting Glypican 3 for advanced hepatocellular carcinoma
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None